Research analysts at StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research note issued on Saturday. The firm set a “hold” rating on the stock.
TherapeuticsMD Price Performance
Shares of TXMD opened at $1.64 on Friday. The company’s fifty day moving average is $1.74 and its two-hundred day moving average is $1.92. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.
Hedge Funds Weigh In On TherapeuticsMD
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Are Penny Stocks a Good Fit for Your Portfolio?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.